Pharma BD Deal Intelligence
A partial win: J&J's ~$2.4B acquisition of Crucell delivered the AdVac platform behind the Ebola vaccine and a 2021 COVID-19 shot, but J&J took roughly $1.3B in impairment charges within two years, and the COVID vaccine itself collapsed commercially and was voluntarily withdrawn in 2023.
Crucell halted shipments of Quinvaxem from its Shingal Korea facility due to microbiological contamination and took a €23M impairment charge during the J&J…
J&J's recommended public offer of €24.75 per share moves the company decisively into vaccines, building on the September 2009 18% strategic stake.
J&J reached 98.89% ownership at the end of the subsequent offering period, clearing the path for delisting and full integration into Janssen Pharmaceuticals.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
J&J reached agreement on October 6, 2010 to acquire remaining ~82% of Crucell for €24.75/share, valuing Crucell at ~€1.75B (~$2.4B). J&J had bought 18% in 2009. Crucell became Janssen Vaccines.
Assessment window: 10yr post-close.
Pediatric combination vaccines protect infants against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in a single injection, simplifying immunization schedules and improving coverage in low- and middle-income countries. The pentavalent format is the WHO/UNICEF/GAVI-recommended platform for routine infant immunization in eligible nations.
At deal time (2010) the global pentavalent vaccine market was supplied primarily by Crucell (Quinvaxem, ~180M cumulative doses since 2006 launch in 50+ GAVI countries), GSK (Tritanrix-HepB+Hib), Sanofi Pasteur, Serum Institute of India (Pentavac), and Panacea Biotec. Crucell's Quinvaxem was the first fully-liquid pentavalent presentation, an important logistics advantage for cold-chain-constrained markets. Crucell additionally brought its PER.C6 cell-line platform (used for adenovirus-vectored vaccines) and AdVac adenovector technology, plus the broadly neutralizing flu antibody CR6261. J&J had taken an 18% stake for €302M in September 2009 and tendered for the remaining ~82% at €24.75/share (~€1.75B / ~$2.4B), a recommended public offer that closed February 2011 with J&J holding >95%. Strategically the acquisition gave J&J a vaccines platform anchoring what became Janssen Vaccines (Leiden), the engine behind J&J's Ebola (Ad26.ZEBOV), HIV, RSV, and ultimately the single-dose Ad26.COV2.S COVID-19 vaccine. Quinvaxem was discontinued in 2016 after WHO prequalification withdrawal and competitive pressure from lower-cost Indian manufacturers.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Crucell N.V. (this deal) | 2010 | $2.4B | 47 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2010 deals · Johnson & Johnson deals · Vaccines deals